The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells

Cancer Immunity

Volumn 8, Issue , 2008, Pages

  Rubin, Bent ^a   Riond, Joëlle ^a   Courtiade, Laetitia ^a   Roullet, Nicolas ^a   Gairin, Jean Edouard ^a  

^a CNRS   (France)

Author keywords

Cultured tumor cells; In vitro; Innate immunity; MHCI; Spleen cells

Indexed keywords

CD11 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; CD1 ANTIGEN; HLA ANTIGEN CLASS 1;

ANIMAL CELL; ARTICLE; CELL INTERACTION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; FIBROBLAST; INNATE IMMUNITY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; IMMUNOLOGY; NATURAL KILLER CELL; NEOPLASM; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD1; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL LINE, TUMOR; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; SPLEEN;

EID: 53449092352     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Tanaka K, Yoshioka T, Bieberich C, Jay G. Role of the major histo-compatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 1988; 6: 359-380. (PMID: 3289570)
2. Dissing S, Geisler C, Rubin B, Plesner T, Claesson M. T cell activation. II. Activation of human T-lymphoma cells by crosslinking of their MHC class I antigens. Cell Immunol 1990; 126: 196-210. (PMID: 2137376)
3. Ozato K, Wan YJ, Orrison BM. Mouse major histocompatibility class I gene expression begins at midsomite stage and is inducible in earlier-stage embryos by interferon. Proc Natl Acad Sci U S A 1985; 82: 2427-2431. (PMID: 2581247)
4. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11: 571-611. (PMID: 8476573)
5. Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ. Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 2001; 166: 1097-1105. (PMID: 11145690)
6. Taieb J, Chaput N, Ménard C, Apetot L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Métivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzman D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L. A novel dendritic cell subset involved in tumor immunosurveillance. Nature Med 2006; 12: 214-219. (PMID: 16444265)
7. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 2007; 56: 227-236. (PMID: 16783578)
8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immuno-editing. Annu Rev Immunol 2004; 22: 329-360. (PMID: 15032581)
9. Ganss R, Arnold B, Hämmerling GJ. Mini-review: Overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 2004; 34: 2635-2641. (PMID: 15368278)
10. Schüler T, Blankenstein T. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 2003; 170: 4427-4431. (PMID: 12707316)
11. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001; 61: 1095-1099. (PMID: 11221838)
12. Yee C, Greenberg P. Modulating T-cell immunity to tumors: new strategies for monitoring T-cell responses. Nat Rev Cancer 2002; 2: 409-419. (PMID: 12189383)
13. Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W, DeLong CJ. Sponta-neous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci U S A 2003; 100: 6682-6687. (PMID: 12724523)
14. Ljunggren HG, Kärre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985; 162: 1745-1759. (PMID: 3877776)
15. Prévost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Tumor-infiltrating lymphocytes exhibit-ing high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998; 161: 2187-2194. (PMID: 9725210)
16. Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmuller G, Koszinowski U, Röcken M. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003; 19: 561-569. (PMID: 14563320)
17. Böhm W, Thoma S, Leithäuser F, Möller P, Schirrmbeck R, Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 1998; 161: 897-908. (PMID: 9670968)
18. Gonthier M, Llobera R, Arnaud J, Rubin B. Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo. J Immunol 2004; 173: 7062-7069. (PMID: 15557204)
19. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 2003; 198: 433-442. (PMID: 12900519)
20. Tanigushi M, Seino KI, Nakayama T. The NKT cell system: Bridging innate and acquired immunity. Nat Immunol 2003; 4: 1164- 1165. (PMID: 14639465)
21. Seaman WE, Sleisenger M, Ericksson E, Koo GC. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 1987; 138: 4539-4544. (PMID: 3584981)
22. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-237. (PMID: 15039760)
23. Eberl G, Lees R, Smiley ST, Tanigushi M, Grusby MJ, MacDonald HR. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol 1999; 162: 6410-6419. (PMID: 10352254)
24. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2: 585-589. (PMID: 11429541)
25. Martin P, del Hoyo GM, Anjuère F, Ruiz SR, Arias CF, Marín AF, Ardavín C. Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8alpha(-) and CD8alpha(+) dendritic cells are generated from CD4(low) lymphoid-committed precursors. Blood 2000; 96: 2511-2519. (PMID: 11001905)
26. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1: 41-49. (PMID: 11905813)
27. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119-126. (PMID: 11248803)
28. Kane KP, Silver ET, Hazes B. Specificity and function of activating Ly-49 receptors. Immunol Rev 2001; 181: 104-114. (PMID: 11513132)
29. Kärre K, Ljunggren HG, Piontel G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678. (PMID: 3951539)
30. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Ben-delak A. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163: 4647-4650. (PMID: 10528160)
31. Crowe NY, Coquet JM, Berzins SP, Kyparissousdis K, Keating R, Pellicci SG, Hayakawa Y, Godfrey DL, Smyth MJ. Differential anti-tumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005; 202: 1279-1288. (PMID: 16275765)
32. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008; 180: 5167-5171. (PMID: 18390697)
33. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 2003; 198: 173-181. (PMID: 12847141)
34. Gumperz JE, Roy C, Makowska A, Lum D, Sigita M, Podrebarac T, Koezuka Y, Porcelli SA, Caedell S, Brenner MB, Behar SM. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000; 12: 211-221. (PMID: 10714687)
35. Takeda K, Oshima H, Hayakawa Y, Akiba H, Atsuka M, Kobata T, Kobayashi K, Ito M, Yagita H, Okumura K. CD27-mediated activation of murine NK cells. J Immunol 2000; 164: 1741-1745. (PMID: 10657619)
36. Velikovsky CA, Deng L, Chlewiski LK, Fernandez MM, Kumar V, Mariuzza RA. Structure of natural killer receptor 2B4 bound to CD48 reveals basis for heterophilic recognition in signalling lymphocyte activation molecule family. Immunity 2007; 27: 572-584. (PMID: 17950006)
37. Chlewicki LK, Velikovsky A, Balakrishnan V, Mariuzza RA, Kumar V. Molecular basis of the dual functions of 2B4 (CD244). J Immunol 2008; 180: 8159-8167. (PMID: 18523281)
38. Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol 2004; 4: 190-198. (PMID: 15039756)
39. Krogsgaard M, Davis MM. How T cells 'see' antigen. Nat Immunol 2005; 6: 239-245. (PMID: 15716973)
40. Gorelik E, Gunji Y, Herberman RB. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity. J Immunol 1988; 140: 2096-2102. (PMID: 3126240)
41. Kawano YI, Tanigushi K, Toshitani A, Nomoto K. Synergistic defense system by cooperative natural effectors against metastasis of B16 melanoma cells in H-2 associated control: Different behavior of H-2+ and H-2- cells in metastatic processes. J Immunol 1986; 136: 4729-4734. (PMID: 3711664)
42. Kakuta S, Tagawa Y, Shibata S, Nanno M, Iwakura Y. Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of anti-tumour host mechanisms. Immunology 2002; 105: 92-100. (PMID: 11849319)
43. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. A critical requirement of IFN gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63: 4095-4100. (PMID: 12874012)
44. Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G, Bussolino F. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001; 166: 3890-3899. (PMID: 11238633)
45. Blohm U, Roth E, Brommer K, Dumrese T, Rosenthal FM, Pircher H. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J Immunol 2002; 169: 5522-5530. (PMID: 12421928)
46. Rubin B. Natural immunity influences the level of autoimmune responses against cancer. Scand J Immunol 2008; in press.
47. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, Wilson CC. Whole recombi-nant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001; 7: 625-629. (PMID: 11329066)
48. Franzusoff A, Duke RC, King TH, Lu Y, Rodell TC. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 2005; 5: 565-575. (PMID: 15934834)
49. Faas SJ, Rothstein JL, Kreider BL, Rovera G, Knowles BN. Phenotypically diverse mouse thymic stromal cell lines which induce proliferation and differentiation of hematopoietic cells. Eur J Immunol 1993; 23: 1201-1214. (PMID: 8500519)
50. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukins 2, 3, 4 or 5 using modified cDNA expression vectors. Eur J Immunol 1988; 18: 97-104. (PMID: 2831066)
51. Schneider C, Newman RA, Sutherland R, Asser U, Greaves MF. A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem 1982; 257: 10766-10769. (PMID: 6955305)